[Comment] HPV Vaccine Scale-Up Is Key to Curb Rising Cervical Cancer Inequalities

Why It Matters

Expanding HPV vaccine coverage can cut millions of preventable cancers, reducing health inequities and easing future treatment costs for global health systems.

Key Takeaways

• LMICs account for 90% of cervical cancer deaths worldwide
• Single‑dose HPV vaccine shows non‑inferior protection to two doses
• Screening coverage remains below 20% in many low‑income regions
• Gavi funding faces political hurdles, risking vaccine rollout delays
• WHO recommends gender‑neutral HPV vaccination to accelerate elimination

Pulse Analysis

Cervical cancer remains the fourth most common cancer among women, with over 600,000 new cases and 340,000 deaths annually. The burden falls disproportionately on low‑ and lower‑middle‑income countries, where fewer than one in five women ever receive a screening test. While high‑income nations have leveraged decades of cytology and recent HPV‑based screening to suppress incidence, the lack of comparable programs in poorer regions fuels a widening health gap. In this context, HPV vaccination emerges as a powerful equalizer, offering primary prevention that does not depend on costly laboratory infrastructure.

Recent modeling studies, including a 2026 Lancet analysis, demonstrate that scaling up vaccination—particularly with a single‑dose schedule proven non‑inferior to the traditional two‑dose regimen—could avert up to 70% of cervical cancer cases in the most vulnerable settings. Single‑dose strategies simplify logistics, reduce costs, and accelerate herd immunity, making them attractive for national immunization programs constrained by limited cold‑chain capacity. Moreover, integrating vaccination with opportunistic screening maximizes impact, as vaccinated cohorts age into the screening‑eligible population, further compressing disease incidence.

Policy and financing, however, remain decisive factors. The World Health Organization’s 2022 position paper calls for gender‑neutral, school‑based vaccination, yet implementation stalls amid political disputes, exemplified by recent Gavi funding delays linked to vaccine composition concerns. Sustainable rollout will require coordinated donor commitments, domestic budget allocations, and community engagement to overcome vaccine hesitancy. By aligning vaccination scale‑up with strengthened screening and robust financing, the global health community can move closer to the WHO’s cervical cancer elimination target, delivering measurable health equity gains worldwide.